Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy - Medical Product Outsourcing
OEM News

Abbott’s Proclaim XR SCS OK’ed for Diabetic Neuropathy

The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication.

Abbott Labs has gained U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN).
 
The Proclaim XR SCS provides an alternative to traditional treatment approaches like oral medication. Those receiving therapy from the system also have access to Abbott’s NeuroSphere virtual clinic, a connected care app for people to communicate with a physician and receive remote treatment adjustments.
 
Proclaim XR SCS’ battery lasts up to 10 years at low-dose settings, according to Abbott.
 
“Diabetic peripheral neuropathy has long plagued people affected by type 1 and type 2 diabetes, often adding another area of disease management on top of their ongoing monitoring of their glucose levels to manage this challenging disease,” Jason E. Pope, MD, DABPM, FIPP, president of Evolve Restorative Center in Santa Rosa, Calif told the press. “Abbott’s Proclaim XR spinal cord stimulation system provides patients with painful diabetic peripheral neuropathy the opportunity to obtain a better quality of life while more seamlessly fitting into their current lifestyles.”
 
Patients can control their therapy with an Apple device, which can also be programmed using the NeuroSphere virtual clinic technology.
 
“As a leader in diabetes care, Abbott is intimately familiar with the challenges people with diabetes encounter daily. This new indication for Proclaim XR will drive meaningful change in the treatment of pain associated with diabetic peripheral neuropathy and will be an important tool for physicians and patients in managing this debilitating condition,” said Pedro Malha, vice president, neuromodulation, Abbott.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters